[go: up one dir, main page]

EA202192488A1 - Антитела против tsg-6 и их применения - Google Patents

Антитела против tsg-6 и их применения

Info

Publication number
EA202192488A1
EA202192488A1 EA202192488A EA202192488A EA202192488A1 EA 202192488 A1 EA202192488 A1 EA 202192488A1 EA 202192488 A EA202192488 A EA 202192488A EA 202192488 A EA202192488 A EA 202192488A EA 202192488 A1 EA202192488 A1 EA 202192488A1
Authority
EA
Eurasian Patent Office
Prior art keywords
applications
antibodies against
tsg
antibodies
pharmaceutical compositions
Prior art date
Application number
EA202192488A
Other languages
English (en)
Inventor
Ричард Брокс
Жаклин М. Мэйсон
Марк Р. Брэй
Original Assignee
Юниверсити Хелт Нетворк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсити Хелт Нетворк filed Critical Юниверсити Хелт Нетворк
Publication of EA202192488A1 publication Critical patent/EA202192488A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

В изобретении предложены новые антитела против TSG-6, фармацевтические композиции, содержащие такие антитела, и терапевтические способы применения таких антител и фармацевтических композиций для лечения заболеваний, например рака или аутоиммунного заболевания.
EA202192488A 2019-03-12 2020-03-11 Антитела против tsg-6 и их применения EA202192488A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962817152P 2019-03-12 2019-03-12
PCT/CA2020/050321 WO2020181376A1 (en) 2019-03-12 2020-03-11 Tsg-6 antibodies and uses therefor

Publications (1)

Publication Number Publication Date
EA202192488A1 true EA202192488A1 (ru) 2022-02-08

Family

ID=72427149

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192488A EA202192488A1 (ru) 2019-03-12 2020-03-11 Антитела против tsg-6 и их применения

Country Status (14)

Country Link
US (1) US20220153834A1 (ru)
EP (1) EP3938389A4 (ru)
JP (1) JP2022522815A (ru)
KR (1) KR20210138674A (ru)
CN (1) CN113748130A (ru)
AU (1) AU2020234533A1 (ru)
BR (1) BR112021017810A2 (ru)
CA (1) CA3129302A1 (ru)
EA (1) EA202192488A1 (ru)
IL (1) IL286216A (ru)
MX (1) MX2021010766A (ru)
SG (1) SG11202109708TA (ru)
TW (1) TW202100551A (ru)
WO (1) WO2020181376A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023192829A2 (en) * 2022-03-28 2023-10-05 University Of Florida Research Foundation, Incorporated Alpha-1 antitrypsin z- and m-specific binding proteins
KR102582500B1 (ko) 2022-10-27 2023-09-26 서울대학교산학협력단 Tnfaip6 -조작된 종양 세포 및 이의 이용
WO2024102759A1 (en) * 2022-11-07 2024-05-16 Board Of Regents, The University Of Texas System Methods involving detecting tnf stimulated gene 6 (tsg-6) for improving anti-tumor responses to immune therapy in cancer patients

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014105810A1 (en) * 2012-12-24 2014-07-03 Abbvie Inc. Prolactin receptor binding proteins and uses thereof
CA2957314A1 (en) * 2014-08-04 2016-02-11 Baylor Research Institute Antagonistic anti-ox40l antibodies and methods of their use
PT3186281T (pt) * 2014-08-28 2019-07-10 Halozyme Inc Terapia de combinação com uma enzima de degradação de hialuronano e um inibidor de pontos de verificação imunológica

Also Published As

Publication number Publication date
US20220153834A1 (en) 2022-05-19
EP3938389A4 (en) 2022-11-09
CN113748130A (zh) 2021-12-03
KR20210138674A (ko) 2021-11-19
SG11202109708TA (en) 2021-10-28
EP3938389A1 (en) 2022-01-19
BR112021017810A2 (pt) 2021-11-23
MX2021010766A (es) 2021-12-10
CA3129302A1 (en) 2020-09-17
JP2022522815A (ja) 2022-04-20
TW202100551A (zh) 2021-01-01
WO2020181376A1 (en) 2020-09-17
AU2020234533A1 (en) 2021-09-16
IL286216A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
EA202092907A1 (ru) Мультиспецифические связывающие белки и их усовершенствования
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
EA202090401A1 (ru) Анти-tim-3 антитела и их применение
EA202191380A1 (ru) Антитела к альфа-синуклеину и их применение
JOP20190187A1 (ar) مترافقات عقار جسم مضاد لـ ccr7
EA202191769A1 (ru) Тубулизины и конъюгаты белок-тубулизин
EA202091747A1 (ru) Составы антитела b7-h4
EA201990400A1 (ru) Соединения и композиции и их применение
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
EA202090372A1 (ru) Универсальные соединения авт и их применение
EA202191476A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA201792561A1 (ru) Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
EA202191478A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA202192488A1 (ru) Антитела против tsg-6 и их применения
EA202190807A1 (ru) Антитела к синуклеину
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
EA201790336A1 (ru) Антитела к ангиопоэтинподобному белку 4 и способы применения
MX2023010661A (es) Moléculas de union al receptor leucocitario humano similar a inmunoglobulina b1 (lilrb1) y al receptor leucocitario humano similar a inmunoglobulina b2 (lilrb2) y usos para las mismas.
MX2021008507A (es) Moleculas que se unen al receptor leucocitario similar a inmunoglobulina subfamilia b miembro 3 (lilrb3) y usos para las mismas.
EA202092122A1 (ru) Антитела против tip-1 и их применения
EA202191758A1 (ru) Пептиды для лечения и профилактики диабета и связанных с ним заболеваний
EA202192254A1 (ru) Fcmr-связывающие молекулы и их применение
EA202190766A1 (ru) Иммуномодуляторы, их композиции и способы применения